Premium
In vitro susceptibilities of feline and canine E scherichia coli and P seudomonas spp. isolates to ticarcillin and ticarcillin–clavulanic acid
Author(s) -
Bennett AB,
Martin PA,
Gottlieb SA,
Govendir M
Publication year - 2013
Publication title -
australian veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.382
H-Index - 59
eISSN - 1751-0813
pISSN - 0005-0423
DOI - 10.1111/avj.12044
Subject(s) - ticarcillin , clavulanic acid , microbiology and biotechnology , in vitro , biology , escherichia coli , amoxicillin , antibiotics , biochemistry , gene
Objectives To investigate in vitro susceptibilities of canine and feline E scherichia coli and canine P seudomonas spp. isolates to ticarcillin and ticarcillin–clavulanic acid ( T / C ). Design In vitro susceptibility testing of bacterial isolates collected from infections. Methods We tested 148 (83 canine and 65 feline) E . coli and 61 canine P seudomonas spp. isolates for susceptibility to T / C using both disc diffusion and Epsilometer tests ( E ‐tests). Additionally, susceptibilities of 96 E . coli and 23 canine P seudomonas spp. isolates were tested via disc diffusion to ticarcillin alone. Results Of the E . coli isolates obtained from canine and feline urine, 92% by disc diffusion and 91% by E ‐tests were susceptible to T / C . Of the canine P seudomonas isolates, 90% by disc diffusion and 82% by E ‐tests were susceptible to T / C . Of the P seudomonas spp. isolates from the canine ear canal or tympanic bullae, 12% of isolates tested via disc diffusion and 23% via E ‐tests were found to be resistant to T / C . The 50% minimum inhibitory concentration of T / C for all feline E . coli isolates was significantly lower than that for all canine E . coli isolates ( P = 0.0031). The addition of clavulanic acid significantly increased the efficacy of ticarcillin against E . coli ( P < 0.0001), but had negligible effect against canine P seudomonas spp. isolates. Conclusion Ticarcillin‐clavulanic acid has reasonable in vitro efficacy against canine and feline E . coli , and canine P seudomonas spp. isolates. However, decisions to use this drug therapeutically must be made on prudent considerations to minimise selection for bacterial resistance.